Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24654886 | 0.87 | UCHL1 (0.34) | UCHL1MGLLPARP1USP30ALDH1A1 | |
| SCHEMBL24657050 | 0.87 | UCHL1 (0.34) | UCHL1MGLLPARP1USP30ALDH1A1 | |
| SCHEMBL24654887 | 0.87 | UCHL1 (0.34) | UCHL1MGLLPARP1USP30ALDH1A1 | |
| SCHEMBL25231301 | 0.86 | UCHL1 (0.38) | UCHL1MGLLPARP1USP30ALDH1A1 | |
| SCHEMBL25527948 | 0.84 | ALDH1A1 (0.34) | UCHL1PARP1GRM5ALDH1A1ADORA1 | |
| SCHEMBL25234104 | 0.84 | MGLL (0.33) | UCHL1MGLLPARP1USP30ALDH1A1 | |
| SCHEMBL25274472 | 0.84 | MGLL (0.33) | UCHL1MGLLPARP1USP30ALDH1A1 | |
| SCHEMBL25276196 | 0.83 | UCHL1 (0.35) | UCHL1MGLLALDH1A1 | |
| SCHEMBL31055666 | 0.80 | JAK2 (0.33) | UCHL1MGLLPARP1ALDH1A1 | |
| SCHEMBL25528021 | 0.80 | GPR119 (0.41) | UCHL1GRM5USP30LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | UCHL1 659/4885MGLL 1/4885PARP1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.